alpha1at deficiency genetic disorder causing emphysema serum alpha1at levels NUMBER shown intrapleural administration aav5alpha1at vector yielded persistent therapeutic alpha1at serum levels antibodies prevalent humans limit use common serotypes gene therapy screened NUMBER aav vectors derived humans nonhuman primates alpha1at expression following intrapleural administration mice rhesus aavrh10 serotype yielded highest levels chosen study following intrapleural administration NUMBER total body transgene expression chest wall diaphragm lung heart intrapleural administration aavrh10alpha1at provided therapeutic alpha1at expression mice higher doses required achieve therapeutic levels female mice male mice intrapleural administration aavrh10alpha1at produced levels naive mice mice administered aav5alpha1at subsequently boosted aavrh10alpha1at vector serum levels increased NUMBER data indicate aavrh10 effective known aav vector intrapleural gene delivery advantage circumventing human immunity aav alpha1 antitrypsin anti aav2 aav5 long term preimmune microg ml aav2 aav5